Attached files
file | filename |
---|---|
EX-31.1 - EX-31.1 - NOVELION THERAPEUTICS INC. | d156162dex311.htm |
EX-31.2 - EX-31.2 - NOVELION THERAPEUTICS INC. | d156162dex312.htm |
EX-32.2 - EX-32.2 - NOVELION THERAPEUTICS INC. | d156162dex322.htm |
10-Q - 10-Q - NOVELION THERAPEUTICS INC. | d156162d10q.htm |
EXHIBIT 32.1
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of QLT Inc. (the Company), on Form 10-Q for the quarterly period ended March 31, 2016 as filed with the Securities and Exchange Commission (the Report) on the date hereof, I, Dr. Geoffrey F. Cox, Interim Chief Executive Officer and acting principal executive officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: May 5, 2016
/s/ Dr. Geoffrey F. Cox |
Dr. Geoffrey F. Cox |
Interim Chief Executive Officer |
(Principal Executive Officer) |